&lt;div&gt;Perspective on the Rezūm&lt;sup&gt;&amp;reg;&lt;/sup&gt; System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy&lt;/div&gt;

Woo, Henry H.; González, Ricardo R.

doi:10.2147/mder.s135378

Cited by 33 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Details of this technology and device have been previously reported. 3,8,9 The primary goal of the procedure is to create continuous, overlapping ablative lesions running parallel to the natural slope of the prostatic urethra, eliminating the tissue interfering with natural function. Confirmation of the contours of the prostate and planned disbursement of thermal lesions is determined at baseline cystoscopy.…”

Section: Methodsmentioning

confidence: 99%

Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study

McVary

Rogers

Roehrborn

2019

Urology

180

140

View full text Add to dashboard Cite

OBJECTIVETo report 4-year outcomes of the randomized controlled trial of water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia. MATERIALS AND METHODSTotal 188 subjects; 135 men ≥50 years old, International Prostate Symptom Score ≥ 13, maximum flow rate (Qmax) ≤15 mL/s and prostate volume 30 to 80 cc treated with Rezum System thermal therapy were followed 4 years; subset of 53 men who requalified for crossover from control to active treatment were followed 3 years. RESULTSLower urinary tract symptoms were significantly improved within ≤3 months after thermal therapy and remained consistently durable (International Prostate Symptom Score 47%, quality of life 43%, Qmax 50%, Benign Prostatic Hyperplasia Impact Index 52%) throughout 4 years (P <.0001); outcomes were similarly sustained in crossover subjects at 3 years. Surgical retreatment rate was 4.4% over 4 years. No disturbances in sexual function were reported. CONCLUSION The minimally invasive thermal therapy provides effective symptom relief and improved quality of life that remains durable for over 4 years. It is applicable to all prostate zones with procedures performed under local anesthesia in an office setting. UROLOGY 126: 171−179, 2019. B y the seventh decade of life approximately 70% of men have histological evidence of histological stromoglandular hyperplasia, namely benign prostatic hyperplasia (BPH). This hyperplasia is commonly associated with progressive development of voiding and storage related lower urinary tract symptoms (LUTS). Several options exist for BPH management with a significant range of invasiveness, efficacy, and cost. The therapy a patient pursues should rely on careful physical evaluation and informed discussion with his provider. Decision making varies according to severity of symptoms, gland size, anatomical features, and efficacy and safety of the different treatments. Minimally invasive surgical treatments (MISTs), both thermal and mechanical expander options, represent alternative intervention before or after any pharmacotherapy.The newest MIST is water vapor thermal therapy using radiofrequency to create thermal energy (Rezum System, Boston Scientific, Marlborough, MA) in the form of water vapor. This therapy was specifically developed as a platform technology for transurethral energy transfer using the convective properties of water, releasing large amounts of stored thermal energy (540 calories/mL H 2 O) as the vapor contacts prostate tissue and condenses back to water.

show abstract

Section: Methodsmentioning

confidence: 99%

Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study

McVary

Rogers

Roehrborn

2019

Urology

180

140

View full text Add to dashboard Cite

show abstract

“…Water vapor thermal therapy with the Rezūm™ System utilizes convectively delivered thermal energy to target ablation of obstructive prostatic tissue. This minimally invasive surgical treatment now has a substantial history as an efficient, effective, and safe modality to treat clinically significant BPH [1][2][3][4]. The procedure is currently recommended for ablation of lateral and median lobes of the prostate [5].…”

Section: Introductionmentioning

confidence: 99%

Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia

McVary

Holland

Beahrs

2019

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Background Water vapor thermal therapy utilizes convectively delivered thermal energy to target ablation of obstructive prostatic tissue. We report results of this thermal therapy for relief of nonneurogenic complete urinary retention associated with BPH. Patients and methods We conducted a retrospective analysis of 38 catheter-dependent men with complete urinary retention consecutively enrolled in a registry in two centers: median age 75.5 years and multiple comorbidities, median prostate volume 58.5 cc (23-153), median 2 failed trials without catheter (TWOCs), and median catheter dependency 3 months (0.3-35). The Rezūm™ System thermal therapy procedure was performed in an ambulatory surgery center with conscious sedation or an office procedure room with a modified periprostatic block. Water vapor injections were customized to the configuration of the hyperplastic gland, including median lobe and/or enlarged central zone. Results Of the 38 treated patients, one was lost to follow-up and 26 of 37 (70.3%) voided spontaneously (mean of 1.6 ± 0.8 TWOCs) and were catheter free a median of 26 days (range 4-65) after the procedure; 18 of these 26 (69%) patients discontinued BPH medications. No significant differences in age, prostate volume, number of water vapor injections, or presence of the median lobe were associated with predicting a successful treatment outcome. Duration of follow-up for 20 catheter-free patients was a median of 475 days or 15.8 months (140-804 days); six patients were followed a median of 31.5 days (0-60). Adverse events were infrequent, mild, and resolved quickly including dysuria in five patients (13%), gross hematuria in four (10.5%), and UTIs in two (2.6%) with indwelling catheters. Conclusions Water vapor thermal therapy may provide an effective and safe alternative to surgical treatment in this group of catheter-dependent patients in complete urinary retention.

show abstract

“…Die Verfügbarkeit neuer Technologien bei der BPS-Therapie erweitert das Spektrum der therapeutischen Optionen und ermöglicht eine individualisierte und kosteneffektive Patientenbehandlung [6]. Eines der neuen Verfahren, das Rezūm-System, appliziert die Wärmeenergie vom Wasserdampf, der mit Radiofrequenz-Strom erzeugt wurde, transurethral per Injektion konvektiv ins Prostatagewebe, um eine sofortige und gezielte Nekrose zu generieren [7]. Die transurethrale konvektive interstitielle Wasserdampfablation (TUKiW) mit dem Rezūm-System führt zu signifikanten und dauerhaften Verbesserungen der LUTS und der Lebensqualität (QoL) mit minimalen passageren perioperativen Nebenwirkungen [8].…”

Section: Introductionunclassified

Blasenentleerungsstörung auf dem Boden einer gutartigen Prostatavergrößerung (BPO)

Martinelli

Herrmann

2018

Aktuel Urol

View full text Add to dashboard Cite

ZusammenfassungDer klassische Therapiealgorithmus zur Behandlung des benignen Prostatasyndroms (BPS) beinhaltet bei Versagen der medikamentösen Therapie einen chirurgischen Ansatz. Neue minimalinvasive Therapien (MIT) bieten das Potenzial für eine schnelle Symptomlinderung bei gleichzeitiger Reduzierung der mit den invasiven Verfahren assoziierten perioperativen Morbidität. Die konvektive interstitielle Radiofrequenz-generierte Wasserdampf-Thermoablation der Prostata mit dem Rezūm®-System ist ein neuartiges MIT zur Behandlung von Männern mit moderaten bis schweren LUTS. Es ermöglicht eine schnelle und dauerhafte Linderung von Speicher- und Entleerungs-LUTS, das Erhalten unzerstörter Sexualfunktion (in Bezug auf sowohl Erektion als auch Ejakulation) und die Verbesserung der Lebensqualität. Das Verfahren bietet sich für die Behandlung eines breiten Spektrums von Prostatadrüsenmorphologien einschließlich intravesikaler Prostataprotrusion, Mittellappen- oder Blasenhalselevation durch zentrale Hyperplasie. Das Rezūm-Verfahren kann auch als Erstlinientherapie zur Krankheitsprogressionsvorbeugung als Alternative zur medikamentösen Langzeit-Polytherapie bei selektionierten Patienten angesetzt werden, um mögliche medikamentenassoziierte Nebenwirkungen zu vermeiden. Dieser Übersichtsartikel befasst sich mit der Beschreibung dieser neuen Technologie und ihrer klinischen Anwendung sowie mit der aktuellen Evidenz, die die Effektivität, die Sicherheit und die Perspektive des Rezūm-Verfahrens bis zum jetzigen Zeitpunkt unterstützt.

show abstract

<div>Perspective on the Rezūm<sup>®</sup> System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy</div>

Cited by 33 publications

References 25 publications

Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study

Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study

Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia

Blasenentleerungsstörung auf dem Boden einer gutartigen Prostatavergrößerung (BPO)

Contact Info

Product

Resources

About